Ginkgo Bioworks Holdings, Inc. (DNA) company profile
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
About Ginkgo Bioworks
Biological Products, (No Diagnostic Substances), SIC 2836
Ginkgo Bioworks Holdings, Inc. is a biotechnology company that provides biological research and development services and tools rather than manufacturing end products. It operates through two segments: cell engineering and biosecurity. In cell engineering, Ginkgo offers research services, automated laboratory hardware, computational models, and biological data assets to support the discovery, optimization, and production of biological products. In biosecurity, it provides biomonitoring programs via Canopy and threat surveillance and analytics through Horizon. Ginkgo serves commercial clients in pharmaceuticals, biotechnology, agriculture, and industrial biotech, as well as government agencies.
Headquartered in Boston, the company coordinates operations and analyzes data from an international partner network. Its facilities include an automated laboratory, up to 3,000 liters of pilot fermentation capacity, and an approximately 12,000-square-foot greenhouse. The company also maintains a collection of over 315,000 agricultural microorganisms and a metagenomic library of more than 2.7 billion genes. Ginkgo deploys biosecurity sampling nodes at strategic locations such as airports and border checkpoints globally.
Summary of the business section of Ginkgo Bioworks's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ginkgo Bioworks Holdings, Inc.
- Founded
- 2008
- Headquarters
- Boston, MA
- Address
- 27 Drydock Avenue, 8th Floor 02210
- Phone
- (877) 442-5362
- Website
- www.ginkgo.bio
- Employees
- 485, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- DNA
- Former tickers
- SRNG until Sep 20, 2021
- Exchange
- NYSE
- IPO date
- Feb 25, 2021
- Shares outstanding
- 67M, Jul 31, 2026
- Public float
- $553.00M, Jun 28, 2024
- Filer category
- Accelerated filer
- Stock splits
- 1-for-40 reverse, Aug 20, 2024
- SEC CIK
- 1830214
- CUSIP
- 37611X209
- ISIN
- US37611X2099
- FIGI
- BBG00YPS1KY3
- Share class FIGI
- BBG00YPS1LT7
- EIN
- 87-2652913
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Reshma P. Shetty | See remarks, Director | 164,705,104 |
| Jason R. Kelly | See remarks, Director | 129,065 |
| Steven P. Coen | See remarks | 50,168 |
| Mark E. Dmytruk | See remarks | 52,132 |
| Christian O. Henry | Director | 19,310 |
| Sri Kosuri | Director | 24,067 |
| Harry Sloan | Director | 271,418 |
| Ross Fubini | Director | 10,822 |
| Kathy Hopinkah Hannan | Director | 15,003 |
| Shyam Sankar | Director | 72,372 |
| Myrtle S. Potter | Director | 10,822 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.71M | $3.71M | $1.73M | $2 | $93 |
| FY2024 | $1.23M | -$248.05K | $1.51M | $2 | $68 |
| FY2023 | $262.02K | -$766.19K | $978.50K | $14 | $67 |
| FY2022 | $262.50K | -$152.52M | $1.23M | $14 | $63 |
| FY2021 | $380.74M | $237.51M | $210.41M | $68 | $84 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Jason Kelly Chief Executive Officer | $250.00K | $5.45M | $5.00K | $5.71M | +364% |
| Reshma Shetty President & Former Chief Operating Officer | $250.00K | $3.22M | $5.00K | $3.48M | +183% |
| Steven Coen Chief Financial Officer | $433.69K | $893.63K | $5.00K | $1.33M | – |
| Mark Dmytruk Former Chief Financial Officer | $212.31K | $169.63K | $5.00K | $386.94K | -78% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Feb 25, 2021
- Offer price
- $10.00
- Securities offered
- 150,000,000
- Gross proceeds
- $1.50B
- Lock-up ends (est.)
- Aug 24, 2021
“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-fifth of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025 we had 485 employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?